|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM100092942 |
| 003 |
DE-627 |
| 005 |
20231222115429.0 |
| 007 |
tu |
| 008 |
231222s1999 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0334.xml
|
| 035 |
|
|
|a (DE-627)NLM100092942
|
| 035 |
|
|
|a (NLM)10075863
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Falta, M T
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Selection of hprt mutant T cells as surrogates for dividing cells reveals a restricted T cell receptor BV repertoire in insulin-dependent diabetes mellitus
|
| 264 |
|
1 |
|c 1999
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 13.04.1999
|
| 500 |
|
|
|a Date Revised 14.11.2007
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright 1999 Academic Press.
|
| 520 |
|
|
|a T cells with somatically acquired mutations in the hypoxanthine-guanine phosphoribosyltransferase (hprt) gene were isolated from patients with insulin-dependent diabetes mellitus (IDDM) as representatives of populations potentially enriched for in vivo activated T cells. TCRB gene V region usage among mutant isolates from individual IDDM patients, but not from normal controls, showed a pronounced preference for BV14 and, to a lesser extent, BV6. Wild-type (nonmutant) isolates did not show such preferences. Extensive in vivo clonal expansions of the BV14 expressing mutant T cells from IDDM patients were revealed by sequence identity of TCRB chain junctional regions. These data support restricted TCRB gene usage in T cell populations enriched for in vivo activated clones in patients with IDDM
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Research Support, U.S. Gov't, P.H.S.
|
| 650 |
|
7 |
|a Receptors, Antigen, T-Cell, alpha-beta
|2 NLM
|
| 650 |
|
7 |
|a Hypoxanthine Phosphoribosyltransferase
|2 NLM
|
| 650 |
|
7 |
|a EC 2.4.2.8
|2 NLM
|
| 700 |
1 |
|
|a Magin, G K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Allegretta, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Steinman, L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Atkinson, M A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Brostoff, S W
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Albertini, R J
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 90(1999), 3 vom: 01. März, Seite 340-51
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:90
|g year:1999
|g number:3
|g day:01
|g month:03
|g pages:340-51
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 90
|j 1999
|e 3
|b 01
|c 03
|h 340-51
|